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Abstract
Low risk prostate cancer patients enrolled in active surveillance (AS) programs commonly
undergo biopsies on a frequent basis for examination of cancer progression. AS programs
employ a fixed schedule of biopsies for all patients. Such fixed and frequent schedules, may
schedule unnecessary biopsies for the patients. Since biopsies have an associated risk of com-
plications, patients do not always comply with the schedule, which increases the risk of delayed
detection of cancer progression. Motivated by the world’s largest AS program, Prostate Can-
cer Research International Active Surveillance (PRIAS), in this paper we present personalized
schedules for biopsies to counter these problems. Using joint models for time to event and
longitudinal data, our methods combine information from historical prostate-specific antigen
(PSA) levels and repeat biopsy results of a patient, to schedule the next biopsy. We also
present methods to compare personalized schedules with existing biopsy schedules.
1 Introduction
Cancer screening is a widely used practice to detect cancer before symptoms appear in otherwise
healthy individuals. A major issue of screening programs that has been observed in many types
of cancers is overdiagnosis (Esserman et al., 2014). To avoid subsequent overtreatment, patients
diagnosed with low grade cancers are commonly advised to join active surveillance (AS) programs.
The goal of AS is to routinely examine the progression of cancer and avoid serious treatments
such as surgery, chemotherapy, or radiotherapy as long as they are not needed. To this end, AS
includes, but is not limited to periodical evaluation of biomarkers pertaining to the cancer, physical
examination, medical imaging, and biopsy.
In this paper we focus on AS programs for prostate cancer (PCa), wherein the decision to
exit AS and start active treatment (e.g., operation, chemotherapy) is typically based on invasive
examinations, such as biopsies (Bokhorst et al., 2016). Biopsies can be reliable, but they are also
painful, and have an associated risk of complications such as urinary retention, hematuria and
sepsis (Loeb et al., 2013). Because of this reason the schedule of biopsies has significant medical
consequences for patients. A frequent schedule of biopsies may help detecting PCa progression
earlier but the corresponding risk of complications will be high. Although such a schedule may
work well for patients with faster progressing cancer, for slowly progressing PCa patients many
unnecessary biopsies may be scheduled. Furthermore, patients do not always comply with such a
schedule, as has been observed by Bokhorst et al. (2015). In the specific case of the world’s largest
AS program, Prostate Cancer Research International Active Surveillance (PRIAS) (Bokhorst et
al., 2016), the compliance rate for biopsies steadily decreased from 81% at year one of follow up,
to 60% at year four, 53% at year seven and 33% at year ten. Such non-compliance can lead to
delayed detection of PCa progression, which may reduce the effectiveness of AS programs.
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This paper is motivated by the need to reduce the medical burden of repeat biopsies while
simultaneously avoiding late detection of PCa progression. For the latter purpose, several AS
programs employ a fixed annual schedule (biopsies with a gap of one year) of biopsies (Tosoian
et al., 2011; Welty et al., 2015). However, given the medical burden of biopsies, most AS programs
also strongly advise against scheduling biopsies more frequently than the annual schedule. The
PRIAS schedule for biopsies is relatively lenient: one biopsy each is scheduled at year one of follow
up, year four, year seven, year ten, and every five years thereafter. However, PRIAS also switches
to the annual schedule if a patient’s prostate-specific antigen (PSA) doubling time, also known
as PSA-DT and measured as the inverse of the slope of the regression line through the base two
logarithm of PSA values, is less than 10 years. We intend to improve upon such fixed schedules by
creating personalized schedules for biopsies. That is, a different schedule for every patient utilizing
their periodically measured serum PSA levels (measured in ng/mL) and repeat biopsy results.
Biopsies are graded using the Gleason score, which takes an integer value between 6 and 10, with
10 corresponding to the most serious state of the cancer. Patients enter AS only if their Gleason
score is 6. When the Gleason score becomes greater than 6, also known as Gleason reclassification
(referred to as GR hereafter), patients are often advised to switch from AS to active treatment.
Hence, for AS programs it is of prime interest to detect GR soonest with least number of biopsies
possible.
Personalized schedules for screening have received much interest in the literature, especially
in the medical decision making context. For diabetic retinopathy, cost optimized personalized
schedules based on Markov models have been developed by Bebu and Lachin (2017). For breast
cancer, personalized mammography screening policy based on the prior screening history and
personal risk characteristics of women, using partially observable Markov decision process (MDP)
models have been proposed by Ayer, Alagoz, and Stout (2012). MDP models have also been used
to develop personalized screening policies for cervical cancer (Akhavan-Tabatabaei, Sánchez, and
Yeung, 2017) and colorectal cancer (Erenay, Alagoz, and Said, 2014). Another type of model called
joint model for time to event and longitudinal data (Rizopoulos, 2012; Tsiatis and Davidian, 2004)
has also been used to create personalized schedules, albeit for the measurement of longitudinal
biomarkers (Rizopoulos et al., 2016). In context of PCa, Zhang et al. (2012) have used partially
observable MDP models to personalize the decision of (not) deferring a biopsy to the next checkup
time during the screening process. The decision is based on the baseline characteristics as well as
a discretized PSA level of the patient at the current check up time.
Our work differs from the above referenced work in certain aspects. Firstly, the schedules we
propose in this paper, account for the latent between-patient heterogeneity. We achieve this using
joint models, which are inherently patient-specific because they utilize random effects. Secondly,
joint models allow a continuous time scale and utilize the entire history of PSA levels. Lastly,
instead of making a binary decision of (not) deferring a biopsy to the next pre-scheduled check up
time, we schedule biopsies at a per patient optimal future time. To this end, using joint models
we first obtain a full specification of the joint distribution of PSA levels and time of GR. We
then use it to define a patient-specific posterior predictive distribution of the time of GR given
the observed PSA measurements and repeat biopsies up to the current check up time. Using
the general framework of Bayesian decision theory, we propose a set of loss functions which are
minimized to find the optimal time of conducting a biopsy. These loss functions yield us two
categories of personalized schedules, those based on expected time of GR and those based on the
risk of GR. In addition we analyze an approach where the two types of schedules are combined.
We also present methods to evaluate and compare the various schedules for biopsies.
The rest of the paper is organized as follows. Section 2 briefly covers the joint modeling
framework. Section 3 details the personalized scheduling approaches we have proposed in this
paper. In Section 4 we discuss methods for evaluation and selection of a schedule. In Section 5
we demonstrate the personalized schedules by employing them for the patients from the PRIAS
program. Lastly, in Section 6, we present the results from a simulation study we conducted to
compare personalized schedules with PRIAS and annual schedule.
2 Joint Model for Time to Event and Longitudinal Outcomes
We start with the definition of the joint modeling framework that will be used to fit a model to the
available dataset, and then to plan biopsies for future patients. Let T ∗i denote the true GR time
for the i-th patient enrolled in an AS program. Let S be the schedule of biopsies prescribed to this
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patient. The corresponding vector of time of biopsies is denoted by T Si = {T
S
i0, T
S
i1, . . . , T
S
iNS
i
;T Sij <
T Sik, ∀j < k}, where N
S
i are the total number of biopsies conducted. Because of the periodical
nature of biopsy schedules, T ∗i cannot be observed directly and it is only known to fall in an
interval li < T
∗
i ≤ ri, where li = T
S
iNS
i
−1
, ri = T
S
iNS
i
if GR is observed, and li = T
S
iNS
i
, ri = ∞ if
GR is not observed yet. Further let yi denote the ni × 1 vector of PSA levels for the i-th patient.
For a sample of n patients the observed data is denoted by Dn = {li, ri,yi; i = 1, . . . , n}.
The longitudinal outcome of interest, namely PSA level, is continuous in nature and thus to
model it the joint model utilizes a linear mixed effects model (LMM) of the form:
yi(t) = mi(t) + εi(t)
= xTi (t)β + z
T
i (t)bi + εi(t),
where xi(t) denotes the row vector of the design matrix for fixed effects and zi(t) denotes the same
for random effects. Correspondingly the fixed effects are denoted by β and random effects by bi.
The random effects are assumed to be normally distributed with mean zero and q × q covariance
matrix D. The true and unobserved PSA level at time t is denoted by mi(t). Unlike yi(t), the
former is not contaminated with the measurement error εi(t). The error is assumed to be normally
distributed with mean zero and variance σ2, and is independent of the random effects bi.
To model the effect of PSA on hazard of GR, joint models utilize a relative risk sub-model.
The hazard of GR for patient i at any time point t, denoted by hi(t), depends on a function of
subject specific linear predictor mi(t) and/or the random effects:
hi(t | Mi(t),wi) = lim
∆t→0
Pr
{
t ≤ T ∗i < t+∆t | T
∗
i ≥ t,Mi(t),wi
}
∆t
= h0(t) exp
[
γTwi + f{Mi(t), bi,α}
]
, t > 0,
where Mi(t) = {mi(v), 0 ≤ v ≤ t} denotes the history of the underlying PSA levels up to time t.
The vector of baseline covariates is denoted by wi, and γ are the corresponding parameters. The
function f(·) parametrized by vector α specifies the functional form of PSA levels (Brown, 2009;
Rizopoulos, 2012; Rizopoulos et al., 2014; Taylor et al., 2013) that is used in the linear predictor of
the relative risk model. Some functional forms relevant to the problem at hand are the following:{
f{Mi(t), bi,α} = αmi(t),
f{Mi(t), bi,α} = α1mi(t) + α2m
′
i(t), with m
′
i(t) =
dmi(t)
dt .
These formulations of f(·) postulate that the hazard of GR at time t may be associated with the
underlying level mi(t) of the PSA at t, or with both the level and velocity m
′
i(t) of the PSA at
t. Lastly, h0(t) is the baseline hazard at time t, and is modeled flexibly using P-splines. More
specifically:
log h0(t) = γh0,0 +
Q∑
q=1
γh0,qBq(t,v),
where Bq(t,v) denotes the q-th basis function of a B-spline with knots v = v1, . . . , vQ and vector
of spline coefficients γh0 . To avoid choosing the number and position of knots in the spline, a
relatively high number of knots (e.g., 15 to 20) are chosen and the corresponding B-spline regression
coefficients γh0 are penalized using a differences penalty (Eilers and Marx, 1996).
For the estimation of joint model’s parameters we use a Bayesian approach. The details of the
estimation method are presented in Web Appendix A of the supplementary material.
3 Personalized Schedules for Repeat Biopsies
Once a joint model for GR and PSA levels is obtained, the next step is to use it to create person-
alized schedules for biopsies. Let us assume that a personalized schedule is to be created for a new
patient j, who is not present in the original sample Dn of patients. Further let us assume that
this patient did not have a GR at his last biopsy performed at time t, and that the PSA levels
are available up to a time point s. The goal is to find the optimal time u > max(t, s) of the next
biopsy.
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3.1 Posterior Predictive Distribution for Time to GR
Let Yj(s) denote the history of PSA levels taken up to time s for patient j. The information from
PSA history and repeat biopsies is manifested by the posterior predictive distribution g(T ∗j ), given
by (conditioning on baseline covariates wi is dropped for notational simplicity hereafter):
g(T ∗j ) = p
{
T ∗j | T
∗
j > t,Yj(s),Dn
}
=
∫
p
{
T ∗j | T
∗
j > t,Yj(s), θ
}
p
(
θ | Dn
)
dθ
=
∫ ∫
p
{
T ∗j | T
∗
j > t, bj , θ
}
p
{
bj | T
∗
j > t,Yj(s), θ
}
p
(
θ | Dn
)
dbjdθ. (1)
The distribution g(T ∗j ) depends on the observed longitudinal history Yj(s) of patient j via the
random effects bj , and on the information from the original datasetDn via the posterior distribution
of the parameters p(θ | Dn), where θ denotes the vector of all parameters.
3.2 Loss Functions
To find the time u of the next biopsy, we use principles from statistical decision theory in a Bayesian
setting (Berger, 1985; Robert, 2007). More specifically, we propose to choose u by minimizing the
posterior expected loss Eg
{
L(T ∗j , u)
}
, where the expectation is taken with respect to g(T ∗j ). The
former is given by:
Eg
{
L(T ∗j , u)
}
=
∫
∞
t
L(T ∗j , u)p
{
T ∗j | T
∗
j > t,Yj(s),Dn
}
dT ∗j .
Various loss functions L(T ∗j , u) have been proposed in literature (Robert, 2007). The ones we
utilize, and the corresponding motivations are presented next.
Given the medical burden of biopsies, ideally only one biopsy performed at the exact time of
GR is sufficient. Hence, neither a time which overshoots the true GR time T ∗j , nor a time which
undershoots is preferred. In this regard, the squared loss function L(T ∗j , u) = (T
∗
j − u)
2 and the
absolute loss function L(T ∗j , u) =
∣∣T ∗j − u∣∣ have the properties that the posterior expected loss is
symmetric on both sides of T ∗j . Secondly, both loss functions have well known solutions available.
The posterior expected loss for the squared loss function is given by:
Eg
{
L(T ∗j , u)
}
= Eg
{
(T ∗j − u)
2
}
= Eg
{
(T ∗j )
2
}
+ u2 − 2uEg(T
∗
j ). (2)
The posterior expected loss in (2) attains its minimum at u = Eg(T
∗
j ), the expected time of GR.
The posterior expected loss for the absolute loss function is given by:
Eg
{
L(T ∗j , u)
}
= Eg
( ∣∣T ∗j − u∣∣ )
=
∫
∞
u
(T ∗j − u)g(T
∗
j )dT
∗
j +
∫ u
t
(u− T ∗j )g(T
∗
j )dT
∗
j . (3)
The posterior expected loss in (3) attains its minimum at the median of g(T ∗j ), given by u =
pi−1j (0.5 | t, s), where pi
−1
j (·) is the inverse of dynamic survival probability pij(u | t, s) of patient j
(Rizopoulos, 2011). It is given by:
pij(u | t, s) = Pr
{
T ∗j ≥ u | T
∗
j > t,Yj(s), Dn
}
, u ≥ t. (4)
For ease of readability we denote pi−1j (0.5 | t, s) as median(T
∗
j ) hereafter.
Even though the mean or median time of GR may be obvious choices from a statistical perspec-
tive, from the viewpoint of doctors or patients, it could be more intuitive to make the decision for
the next biopsy by placing a cutoff 1− κ, where 0 ≤ κ ≤ 1, on the dynamic incidence/risk of GR.
This approach would be successful if κ can sufficiently well differentiate between patients who will
obtain GR in a given period of time, and those who will not. This approach is also useful when
patients are apprehensive about delaying biopsies beyond a certain risk cutoff. Thus, a biopsy can
be scheduled at a time point u such that the dynamic risk of GR is higher than a certain threshold
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1−κ, beyond u. To this end, the posterior expected loss for the following multilinear loss function
can be minimized to find the optimal u:
Lk1,k2(T
∗
j , u) =
{
k2(T
∗
j − u), k2 > 0 if T
∗
j > u,
k1(u− T
∗
j ), k1 > 0 otherwise.
(5)
where k1, k2 are constants parameterizing the loss function. The posterior expected lossEg
{
Lk1,k2(T
∗
j , u)
}
obtains its minimum at u = pi−1j
{
k1/(k1 + k2) | t, s
}
(Robert, 2007). The choice of the two con-
stants k1 and k2 is equivalent to the choice of κ = k1/(k1 + k2).
In practice, for some patients we may not have sufficient information to accurately estimate
their PSA profile. The resulting high variance of g(T ∗j ) could make using a measure of central
tendency such as mean or median time of GR unreliable (i.e., overshooting the true T ∗j by a big
margin). In such occasions, the approach based on dynamic risk of GR could be more robust. This
consideration leads us to a hybrid approach, namely, to select u using dynamic risk of GR based
approach when the spread of g(T ∗j ) is large, while using Eg(T
∗
j ) or median(T
∗
j ) when the spread
of g(T ∗j ) is small. What constitutes a large spread will be application-specific. In PRIAS, within
the first 10 years, the maximum possible delay in detection of GR is three years. Thus we propose
that if the difference between the 0.025 quantile of g(T ∗j ), and Eg(T
∗
j ) or median(T
∗
j ) is more than
three years then proposals based on dynamic risk of GR be used instead.
3.3 Estimation
Since there is no closed form solution available for Eg(T
∗
j ), for its estimation we utilize the following
relationship between Eg(T
∗
j ) and pij(u | t, s):
Eg(T
∗
j ) = t+
∫
∞
t
pij(u | t, s)du. (6)
There is no closed form solution available for the integral in (6), and hence we approximate it using
Gauss-Kronrod quadrature. We preferred this approach over Monte Carlo methods to estimate
Eg(T
∗
j ) from g(T
∗
j ), because sampling directly from g(T
∗
j ) involved an additional step of sampling
from the distribution p(T ∗j | T
∗
j > t, bj , θ), as compared to the estimation of pij(u | t, s) (Rizopoulos,
2011). The former approach was thus computationally faster.
As mentioned earlier, selection of the optimal biopsy time based on Eg(T
∗
j ) alone will not be
practically useful when the varg(T
∗
j ) is large, which is given by:
varg(T
∗
j ) = 2
∫
∞
t
(u− t)pij(u | t, s)du−
{∫ ∞
t
pij(u | t, s)du
}2
. (7)
Since a closed form solution is not available for the variance expression, it is estimated similar to
the estimation of Eg(T
∗
j ). The variance depends both on last biopsy time t and PSA history Yj(s).
The impact of the observed information on variance is demonstrated in Section 5.2.
For schedules based on dynamic risk of GR, the value of κ dictates the biopsy schedule and
thus its choice has important consequences. Often it may be chosen on the basis of the amount of
risk that is acceptable to the patient. For example, if the maximum acceptable risk is 5%, then
κ = 0.95.
In cases where κ cannot be chosen on the basis of the input of the patients, we propose to
automate the choice of κ. More specifically, we propose to choose a threshold κ for which a
binary classification accuracy measure (López-Ratón et al., 2014), discriminating between cases
and controls, is maximized. In PRIAS, cases are patients who experience GR and the rest are
controls. However, a patient can be in control group at some time t and in the cases at some future
time point t+∆t, and thus time dependent binary classification is more relevant. In joint models,
a patient j is predicted to be a case if pij(t + ∆t | t, s) ≤ κ and a control if pij(t + ∆t | t, s) > κ
(Rizopoulos, 2016; Rizopoulos, Molenberghs, and Lesaffre, 2017). In this work we choose the time
window ∆t to be one year. This because, in AS programs at any point in time, it is of interest to
identify patients who may obtain GR in the next one year from those who do not, so that they
can be provided immediate attention (in exceptional cases a biopsy within an year of the last one).
As for the choice of the binary classification accuracy measure, we require a measure which is in
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line with the goal to focus on patients whose true time of GR falls in the time window ∆t. To this
end, a measure which combines both sensitivity and precision is the F1 score. It is defined as:
F1(t,∆t, s) = 2
TPR(t,∆t, s) PPV(t,∆t, s)
TPR(t,∆t, s) + PPV(t,∆t, s)
,
TPR(t,∆t, s) = Pr
{
pij(t+∆t | t, s) ≤ κ | t < T
∗
i ≤ t+∆t
}
,
PPV(t,∆t, s) = Pr
{
t < T ∗i ≤ t+∆t | pij(t+∆t | t, s) ≤ κ
}
.
where TPR(·) and PPV(·) denote time dependent true positive rate (sensitivity) and positive
predictive value (precision), respectively. The estimation for both is similar to the estimation of
AUC(t,∆t, s) given by Rizopoulos, Molenberghs, and Lesaffre (2017). Since a high F1 score is
desired, the optimal value of κ is argmaxκ F1(t,∆t, s). In this work we compute the latter using a
grid search approach. That is, first F1 is computed using the available dataset over a fine grid of
κ values between 0 and 1, and then κ corresponding to the highest F1 is chosen. Furthermore, in
this paper we use κ chosen only on the basis of F1 score.
3.4 Algorithm
The aforementioned personalized schedules, schedule biopsy at a time u > max(t, s). However, if
time u < T ∗j , then GR is not detected at u and at least one more biopsy is required at an optimal
time unew > max(u, s). This process is repeated until GR is detected. To aid in medical decision
making, we elucidate this process via an algorithm in Figure 1. Since AS programs strongly advise
that biopsies are conducted at a gap of at least one year, when u− t < 1, the algorithm postpones
u to t+ 1, because it is the time nearest to u, at which the one year gap condition is satisfied.
4 Evaluation of Schedules
Given a particular schedule S of biopsies, our next goal is to evaluate the schedule and to compare
it with other schedules. To this end, we first present the methods to evaluate the biopsy schedules
and then discuss the choice of a schedule.
We evaluate a schedule S using two criteria, namely the number of biopsies NSj ≥ 1 a schedule
conducts for the j-th patient to detect GR, and the offset OSj ≥ 0 by which it overshoots the true
GR time T ∗j . The offset O
S
j is defined as O
S
j = T
S
jNS
j
− T ∗j , where T
S
jNS
j
≥ T ∗j is the time at which
GR is detected. Our interest lies in the joint distribution p(NSj , O
S
j ) of the number of biopsies and
the offset. Given the medical burden of biopsies, ideally only one biopsy with zero offset should
be conducted. Hence, realistically we should select a schedule with a low mean number of biopsies
E(NSj ) as well a low mean offset E(O
S
j ). It is also desired that a schedule has low variance of the
number of biopsies var(NSj ), as well as low variance of the offset var(O
S
j ), so that the schedule
works similarly for most patients. Quantiles of p(NSj ) may also be of interest. For example, it may
be desired that a schedule detects GR with at most two biopsies in 95% of the patients.
4.1 Choosing a Schedule
Given the multiple criteria for evaluation of a schedule, the next step is to use them to select a
schedule. Using principles from compound optimal designs (Läuter, 1976) we propose to choose a
schedule S which minimizes a loss function of the following form:
L(S) =
R∑
r=1
ηrRr(N
S
j ). (8)
where Rr(·) is an evaluation criteria based on either the number of biopsies or the offset (for
brevity of notation, only NSj is used in the equation above). Some examples of Rr(·) are mean,
median, variance and quantile function. Constants η1, . . . , ηR, where 0 ≤ ηr ≤ 1 and
∑R
r=1 ηr = 1,
are weights to differentially weigh-in the contribution of each of the R criteria. An example loss
function is:
L(S) = η1E(N
S
j ) + η2E(O
S
j ). (9)
6
Enter Active Surveillance.
1. Measure PSA and Gleason at induction.
2. Reset s = t = T nv = 0.
3. Reset u = upv =∞.
(1) Update g(T ∗j ).
(2) Set u = new optimal u.
u ≤ upv Set u = upv.
(1) Set s = snv.
(2) Measure PSA at s.
u ≤ s
Set u = s. u − t ≥ 1 u > snv
Set upv = u.
Set u = t + 1. Conduct biopsy at u.
Gleason > 6
(1) Set t = u.
(2) Reset u = upv =∞.
Remove patient from AS
Yes
Yes
No
No
Yes
Yes
No
Yes
No
No
Figure 1: Algorithm for creating a personalized schedule for patient j. The time of the latest
biopsy is denoted by t. The time of the latest available PSA measurement is denoted by s. The
proposed personalized time of biopsy is denoted by u. The time at which a repeat biopsy was
proposed on the last visit to the hospital is denoted by upv. The time of the next visit for the
measurement of PSA is denoted by T nv.
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The choice of η1 and η2 is not easy, because biopsies have associated medical risks and consequently
the cost of an extra biopsy cannot be quantified or compared to a unit increase in offset easily.
To obviate this problem we utilize the equivalence between compound and constrained optimal
designs (Cook and Wong, 1994). More specifically, it can be shown that for any η1 and η2 there
exists a constant C > 0 for which minimization of loss function in (9) is equivalent to minimization
of the loss function subject to the constraint that E(OSj ) < C. That is, a suitable schedule is the
one which conducts the least number of biopsies to detect GR while simultaneously guaranteeing
an offset less than C. The choice of C now can be based on the protocol of AS program. In
the more generic case in (8), a schedule can be chosen by minimizing RR(·) under the constraint
Rr(·) < Cr; r = 1, . . . , R− 1.
5 Demonstration of Personalized Schedules
To demonstrate how the personalized schedules work, we apply them to the patients enrolled in
PRIAS. To this end, we divide the PRIAS dataset into a training dataset with 5264 patients and
a demonstration dataset with three patients who never experienced GR. We fit a joint model to
the training dataset and then use it to create personalized schedules for patients in demonstration
dataset. We fit the joint model using the R package JMbayes (Rizopoulos, 2016), which uses the
Bayesian methodology to estimate the model parameters.
5.1 Fitting the Joint Model to PRIAS Dataset
The training dataset contains age at the time of induction in PRIAS, PSA levels and the time
interval in which GR is detected, for 5264 prostate cancer patients. PSA was measured at every
three months for the first two years and every six months thereafter. To detect GR, biopsies were
conducted as per the PRIAS schedule (Section 1). For the longitudinal analysis of PSA we use
log2 PSA measurements instead of the raw data (Nieboer et al., 2015). The longitudinal sub-model
of the joint model we fit is given by:
log2 PSA(t) = β0 + β1(Age− 70) + β2(Age− 70)
2 +
4∑
k=1
βk+2Bk(t,K)
+ bi0 + bi1B7(t, 0.1) + bi2B8(t, 0.1) + εi(t).
(10)
where Bk(t,K) denotes the k-th basis function of a B-spline with three internal knots at K =
{0.1, 0.5, 4} years, and boundary knots at zero and seven years. The spline for the random effects
consists of one internal knot at 0.1 years and boundary knots at zero and seven years. The choice
of knots was based on exploratory analysis as well as on model selection criteria AIC and BIC.
Age of patients was median centered to avoid numerical instabilities during parameter estimation.
For the relative risk sub-model the hazard function we fit is given by:
hi(t) = h0(t) exp
{
γ1(Age− 70) + γ2(Age− 70)
2 + α1mi(t) + α2m
′
i(t)
}
. (11)
where α1 and α2 are measures of strength of the association between hazard of GR and log2 PSA
value mi(t) and log2 PSA velocity m
′
i(t), respectively. Since the PRIAS schedule depends only on
the observed PSA values (via PSA-DT), the interval censoring observed in PRIAS is independent
and non informative of the underlying health of the patient.
From the joint model fitted to the PRIAS dataset we found that only log2 PSA velocity was
strongly associated with hazard of GR. For any patient, a unit increase in log2 PSA velocity led
to an 11 fold increase in the hazard of GR. The parameter estimates for the fitted joint model are
presented in detail in Web Appendix C of the supplementary material.
5.2 Personalized Schedules for the First Demonstration Patient
Using the demonstration dataset, we next present the functioning of personalized schedules based
on expected time of GR and dynamic risk of GR. The evolution of PSA, time of last biopsy and
proposed biopsy times for the first demonstration patient are shown in the top panel of Figure
2. We can see the combined effect of decreasing PSA levels and a negative repeat biopsy on
personalized schedules, between year three and year 4.5 for this patient. In accordance with the
8
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Figure 2: Top panel: Evolution of PSA, history of repeat biopsies and corresponding personal-
ized schedules for the first demonstration patient. Bottom Panel: History of repeat biopsies and
SDg(T
∗
j ) =
√
varg(T ∗j ) over time for the first demonstration patient.
two negative repeat biopsies and consistently decreasing PSA, the proposed time of biopsy based
on dynamic risk of GR increases from 14 years to 15 years in this period. Whereas, the proposed
time of biopsy based on expected time of GR increases from 16.6 years to 18.8 years. We can also
see in the bottom panel of Figure 2 that after each negative repeat biopsy, SD[T ∗j ] =
√
varg(T ∗j )
decreases sharply. Thus, if the expected time of GR based approach is used, then the offset OSj will
be smaller on average for biopsies scheduled after the second repeat biopsy than those scheduled
after the first repeat biopsy.
The demonstration of personalized schedules for the two other patients from the demonstration
data set is presented in Web Appendix D of the supplementary material.
6 Simulation Study
The application of personalized schedules for patients from PRIAS demonstrated that these sched-
ules adapt according to the historical data of each patient. However we could not perform a full
scale comparison between personalized and PRIAS schedule, because the true time of GR was
not known for the PRIAS patients. To this end, we conducted a simulation study comparing
personalized schedules with PRIAS and annual schedule, whose details are presented next.
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6.1 Simulation Setup
First we assume a population of patients enrolled in AS, with the same entrance criteria as that
of PRIAS. The PSA and hazard of GR for patients from this population follow a joint model of
the form postulated in Section 5.1, with parameters equal to the posterior mean of parameters
estimated from the joint model fitted to PRIAS dataset (Web Appendix C of the supplementary
material). We further assume that there are three equal sized subgroups G1, G2 and G3 of patients
in the population, differing in the baseline hazard of GR. This was done because we wanted to test
the performance of different schedules for a population with a mixture of patients, namely those
with faster progressing PCa, as well as those with slowly progressing PCa. For the three subgroups
we use a Weibull distributed baseline hazard with the following shape and scale parameters (k, λ):
(1.5, 4), (3, 5) and (4.5, 6) for G1, G2 and G3, respectively. The effect of these parameters is that
the mean GR time is lowest in G1 (faster progressing PCa) and highest in G3 (slowly progressing
PCa).
From this population we have sampled 500 datasets with 1000 patients each. Patients are
randomly assigned to a subgroup. Further, each dataset is split into a training (750 patients) and
a test (250 patients) part. The k-th simulated training datasetDk is given byDk = {lki, rki,yki; i =
1, . . . , 750}, where yki denote the PSA measurements for the i-th patient in D
k. The frequency of
PSA measurements is same as that in PRIAS. Other than simulating a true GR time T ∗ki, we also
generate a random and non-informative censoring time Cki. When T
∗
ki < Cki, then lki = rki = T
∗
ki,
otherwise lki = Cki and rki =∞. For the test patients, censoring time is not generated.
We next fit a joint model of the specification given in (10) and (11) to each of the Dk, k =
1, . . . , 500, and obtain a MCMC sample from the posterior distribution p(θ | Dk). We then obtain
g(T ∗kl) for each of the l-th test patient of the k-th data set and conduct hypothetical biopsies for
him. For every patient we conduct biopsies using the following six types of schedules (abbreviated
names in parenthesis): personalized schedules based on expected time of GR (Exp. GR time)
and median time of GR (Med. GR time), personalized schedules based on dynamic risk of GR
(Dyn. risk GR), a hybrid approach between median time of GR and dynamic risk of GR (Hybrid),
PRIAS schedule and annual schedule. The biopsies are conducted iteratively in accordance with
the algorithm in Figure 1.
To compare the aforementioned schedules we require estimates of the various criteria based on
offset and number of biopsies conducted to detect GR (Section 4). To this end, we compute pooled
estimates of each of the E(NSj ), var(N
S
j ), E(O
S
j ) and var(O
S
j ), as below:
̂E(OSj ) = ∑500k=1 nk ̂E(OSk )∑500
k=1 nk
,
̂var(OSj ) = ∑500k=1(nk − 1) ̂var(OSk )∑500
k=1(nk − 1)
,
where nk denotes the number of test patients,
̂E(OSk ) = ∑nkl=1OSkl/nk is the estimated mean and̂var(OSk ) = ∑nkl=1 {OSkl − ̂E(OSk )}2/(nk − 1) is the estimated variance of the offset for the k-th
simulation. The estimates for number of biopsies are obtained similarly.
6.2 Results
The pooled estimates of the aforementioned criteria are summarized in Table 1. In addition, mean
offset is plotted against mean number of biopsies conducted to detect GR in Figure 3. From the
figure it is evident that across the schedules there is an inverse relationship between E(NSj ) and
E(OSj ). For example, the annual schedule conducts on average 5.2 biopsies to detect GR, which
is the highest among all schedules, however it has the least average offset of 6 months as well.
On the other hand the schedule based on expected time of GR conducts only 1.9 biopsies on
average to detect GR, the least among all schedules, but it also has the highest average offset of
15 months. The schedule based on median time of GR performs similar to that based on expected
time of GR. Since the annual schedule attempts to contain the offset within an year it has the least
SD(OSj ) =
√
var(OSj ). However to achieve so, it conducts a wide range of number of biopsies from
patient to patient, i.e., highest SD(NSj ) =
√
var(NSj ). Schedules based on expected and median
time of GR perform the opposite of annual schedule in terms of SD(NSj ) and SD(O
S
j ).
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Table 1: Estimated mean and standard deviation of the number of biopsies and offset (months).
a) All subgroups
Schedule E(NSj ) E(O
S
j ) SD(N
S
j ) SD(O
S
j )
Annual 5.24 6.01 2.53 3.46
PRIAS 4.90 7.71 2.36 6.31
Dyn. risk GR 4.69 6.66 2.19 4.38
Hybrid 3.75 9.70 1.71 7.25
Med. GR time 2.06 13.88 1.41 11.80
Exp. GR time 1.92 15.08 1.19 12.11
b) Subgroup G1
Schedule E(NSj ) E(O
S
j ) SD(N
S
j ) SD(O
S
j )
Annual 4.32 6.02 3.13 3.44
PRIAS 4.07 7.44 2.88 6.11
Dyn. risk GR 3.85 6.75 2.69 4.44
Hybrid 3.25 10.25 2.16 8.07
Med. GR time 1.84 20.66 1.76 14.62
Exp. GR time 1.72 21.65 1.47 14.75
c) Subgroup G2
Schedule E(NSj ) E(O
S
j ) SD(N
S
j ) SD(O
S
j )
Annual 5.18 5.98 2.13 3.47
PRIAS 4.85 7.70 2.00 6.29
Dyn. risk GR 4.63 6.66 1.82 4.37
Hybrid 3.68 10.32 1.37 7.45
Med. GR time 1.89 12.33 1.16 9.44
Exp. GR time 1.77 13.54 0.98 9.83
d) Subgroup G3
Schedule E(NSj ) E(O
S
j ) SD(N
S
j ) SD(O
S
j )
Annual 6.20 6.02 1.76 3.46
PRIAS 5.76 7.98 1.71 6.51
Dyn. risk GR 5.58 6.58 1.56 4.33
Hybrid 4.32 8.55 1.26 5.91
Med. GR time 2.45 8.70 1.15 6.32
Exp. GR time 2.27 10.09 0.99 7.47
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Figure 3: Estimated mean number of biopsies and mean offset (months) for the 6 schedules, using
all simulated patients.
The PRIAS schedule conducts only 0.3 biopsies less than the annual schedule, but with a higher
variance of offset, it does not guarantee early detection for everyone. If we compare the PRIAS
schedule with dynamic risk of GR based schedule, we can see that the latter performs slightly
better than PRIAS schedule in all four criteria. The hybrid approach combines the benefits of
methods with low E(NSj ) and SD(N
S
j ), and methods with low E(O
S
j ) and SD(O
S
j ). It conducts
1.5 biopsies less than the annual schedule on average and with a E(OSj ) of 9.7 months it detects
GR within an year since its occurrence. Moreover, it has both SD(NSj ) and SD(O
S
j ) comparable
to PRIAS.
The performance of each schedule differs for the three subgroups G1, G2 and G3. The annual
schedule remains the most consistent across subgroups in terms of the offset, but it conducts 2
extra biopsies for subgroup G3 (slowly progressing PCa) than G1 (faster progressing PCa). The
performance of schedule based on expected time of GR is the most consistent in terms of number
of biopsies but it detects GR an year later on average in subgroup G1 than G3. For the dynamic
risk of GR based schedule and the hybrid schedule the dynamics are similar to that of the annual
schedule. Unlike the latter two schedules, the PRIAS schedule not only conducts more biopsies in
G3 than G1 but also detects GR later in G3 than G1.
The choice of a suitable schedule using (8) depends on the chosen criteria for evaluation of
schedules. For example, the schedule based on dynamic risk of GR is suitable if on average the
least number of biopsies are to be conducted to detect GR, while simultaneously making sure
that at least 90% of the patients have an average offset less than one year (Figure 4 and 5). The
schedule based on expected time of GR is suitable if on average the least number of biopsies are
to be conducted to detect GR, while simultaneously making sure that at least 90% of the patients
have an average offset less than three years. If a stricter cutoff is required on offset the hybrid
approach may be suitable, since it conducts only 3.8 biopsies on average while guaranteeing an
offset of two years for 95% of the patients and three years for 99.9% of the patients. Besides if
further cutoffs are required on variance of number of biopsies or offset they are not too high either
for the hybrid approach.
7 Discussion
In this paper we presented personalized schedules for surveillance of PCa patients. The problem
at hand was the following: Low risk PCa patients enrolled in AS have to undergo repeat biopsies
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Figure 5: Boxplot showing variation in biopsy offset (months) for different methods, using all
simulated patients.
on a frequent basis for examination of PCa progression, and since biopsies have an associated
risk of complications, not all patients comply with the schedule of biopsies. This may reduce
the effectiveness of AS programs because detection of PCa progression is delayed. To approach
these problems we proposed personalized schedules based on joint models for time to event and
longitudinal data. At any given point in time, the proposed personalized schedules utilize a patient’s
information from historical PSA measurements and repeat biopsies conducted up to that time. We
proposed two different classes of personalized schedules, namely schedules based on expected and
median time of GR of a patient, and schedules based on dynamic risk of GR. In addition we also
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proposed a combination (hybrid approach) of these two approaches, which is useful in scenarios
where variance of time of GR for a patient is high. We then proposed criteria for evaluation of
various schedules and a method to select a suitable schedule.
We demonstrated using the PRIAS dataset that the personalized schedules adjust the time of
biopsy on the basis of results from historical PSA measurements and repeat biopsies, even when the
two are not in concordance with each other (Web Appendix D). Secondly, we conducted a simulation
study to compare various schedules. We observed that the schedules based on expected and median
time of GR conduct only two biopsies on average to detect GR, which is promising compared to
PRIAS (4.9 biopsies) and annual schedule (5.2 biopsies). We also observed that the performance of
the schedules depends on the true GR time of the patient. For example, in simulated patients who
have a slowly progressing PCa (subgroup G3), personalized schedule based on expected time of GR
detects GR one year earlier on average compared to patients who have a faster progressing PCa
(subgroup G1), while conducting approximately the same number of biopsies for both subgroups.
For subgroup G1, the annual or PRIAS schedule may be preferred because they detect GR at 6
and 7.4 months since its occurrence, respectively. However for slowly progressing PCa patients up
to 6 biopsies were needed to detect GR at 6 and 8 months, respectively. In such scenarios, that is,
where it is not known in advance if the patient will have a faster or slower progression of PCa, the
hybrid approach provides an interesting alternative. This because, it conducts one biopsy less than
the annual schedule in faster progressing PCa patients while detecting GR at 10.3 months since
its occurrence on average. Whereas, for slowly progressing PCa patients it conducts two biopsies
less than the annual schedule while detecting GR at 8.6 months since its occurrence on average.
While each of the personalized schedules have their own advantages and disadvantages, they
also offer multiple choices to the AS programs to choose one as per their requirements, instead of
choosing a common fixed schedule for all patients. In this regard, we proposed to choose schedules
which conduct as less biopsies as possible while restricting the offset to be below a AS program
specific threshold, or vice versa. There is also potential to develop more personalized schedules.
For example, using loss functions which asymmetrically penalize overshooting/undershooting the
target GR time can be interesting. Furthermore, for dynamic risk of GR based schedules, it is
also possible to choose κ using other binary classification accuracy measures or as per patient’s
wish (Web Appendix E). Although in this work we assumed that the time of GR was interval
censored, in reality the Gleason scores are susceptible to inter-observer variation (Carlson et al.,
1998). Models and schedules which account for error in measurement of time of GR will be
interesting to investigate further. Lastly, there is potential for including diagnostic information
from magnetic resonance imaging (MRI) or DRE. Unlike PSA levels, such information may not
always be continuous in nature, in which case our proposed methodology can be extended by
utilizing the framework of generalized linear mixed models.
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